Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
20%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
2
18%
Ph phase_1
2
18%
Ph phase_3
2
18%
Ph phase_2
4
36%
Ph phase_4
1
9%

Phase Distribution

2

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 32 (18.2%)
Phase 41 (9.1%)
N/A2 (18.2%)

Trials by Status

terminated19%
completed1091%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11